Biotechnology News and Research

RSS

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

NKT, DSM sign contract to develop therapeutics based on natural killer T cells

DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced the signing of a contract with NKT Therapeutics, Inc. based in Waltham, Mass, USA, the biotechnology company that focuses on developing therapeutics based on unique immune cells called natural killer T cells.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2010.

8 Feb 2011

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

JumpStart Ventures, the non-profit that invests in and partners with innovative, early-stage companies in Northeast Ohio, and Cleveland Clinic, announced a combined investment commitment of $500,000 in SironRX Therapeutics, Inc. The Cleveland-based company is developing a topical therapy to enhance healing of and decrease scar formation in wounds.

8 Feb 2011

Luminex 2010 revenue increases 17% to $141.6 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2010. Recent

From Luminex 8 Feb 2011

Munich research team provides promising alternative to DNA-based procedures

Defects in the genome are the cause of many diseases. Gene therapy - direct replacement of mutant genes by intact DNA copies - offers a means of correcting such defects. Now a research team based at the Medical Center of the University of Munich, and led by Privatdozent Dr. Carsten Rudolph, has taken a new approach that avoids DNA delivery.

8 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2010.

7 Feb 2011

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

DermTech International, a biotechnology company dedicated to bringing genomic medicine to dermatologists, today announced that the discovery data on its new genomic assay for melanoma have been published in the British Journal of Dermatology.

7 Feb 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

Maxygen distributes Codexis's shares to its stockholders for U.S. Federal income tax purposes

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its distributions of Codexis, Inc. common stock and cash in December 2010 will be classified as a return of capital to its stockholders for U.S. Federal income tax purposes.

5 Feb 2011

New understanding of how host and foreign structures are distinguished by front-line defence mechanism

This week, the highly-respected US Academy of Sciences journal (PNAS) published an article describing how the first line of defence of the human immune system distinguishes between microbes and the body's own structures.

5 Feb 2011

MetaMorphix announces sale under Chapter 11

MetaMorphix, Inc., an animal biotechnology company, announced its intention to sell all, or substantially all, of its assets as part of its reorganization under a sale in Chapter 11 pursuant to section 363 of the Bankruptcy Code. The Company also announced that American MedTech Advisors has been retained to assist in the sale of the Company.

5 Feb 2011

NYSE Amex accepts Palatin's exchange listing compliance plan

Palatin Technologies, Inc. reported that its exchange listing compliance plan has been accepted by the NYSE Amex. Palatin has been granted an extension until May 26, 2011 to regain compliance with stockholders' equity requirements under Section 1003(a)(iii) of the NYSE Amex Company Guide and until February 28, 2011 to regain compliance with financial condition continued listing requirements under Section 1003(a)(iv).

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

Partek signs distribution agreement with Life Technologies

Partek Incorporated, a global leader in bioinformatics software, announced today the signing of a distribution agreement with Life Technologies Corporation, a provider of next-generation DNA sequencing technology. The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies' next-generation sequencing devices.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

How body's first line of defence distinguishes between microbes and own structures

4 Feb 2011

Cholesterol efflux capacity may protect against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol are associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

4 Feb 2011

Biotechnology News and Research

Elan 2010 total revenue increases 5% to $1,169.7 million

NKT, DSM sign contract to develop therapeutics based on natural killer T cells

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Teva fourth quarter net sales increase 16% to record $4.4 billion

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

Luminex 2010 revenue increases 17% to $141.6 million

Munich research team provides promising alternative to DNA-based procedures

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

AMRI fourth quarter total revenue increases 12% to $48.6 million

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Maxygen distributes Codexis's shares to its stockholders for U.S. Federal income tax purposes

New understanding of how host and foreign structures are distinguished by front-line defence mechanism

MetaMorphix announces sale under Chapter 11

NYSE Amex accepts Palatin's exchange listing compliance plan

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Partek signs distribution agreement with Life Technologies

ECR launches sleep aid product, Zolpimist Oral Spray in the US

How body's first line of defence distinguishes between microbes and own structures

Cholesterol efflux capacity may protect against heart disease: Study

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News